Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 efgartigimod PH20 SC trial in adults with CIDP
NL-OMON54028Phase 2Active, not recruiting
- Sponsor
- argenx
- Start
- Sep 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of efgartigimod alfa in chronic inflammatory demyelinating polyneuropathy (CIDP) (3 arms), sponsored by argenx. Primary endpoints: Percentage of patients with confirmed ECI and Time to first confirmed adjusted INCAT deterioration. Started Sep 2021; status: active, not recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NL-OMON54028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54028.